ERBB2 and non-small cell lung carcinoma: For instance, trastuzumab deruxtecan (DS-8201) utilizes a cleavable linker that releases its payload (DXd) preferentially in HER2-mutated NSCLC cells, achieving an ORR of 58.3% with reduced systemic toxicity.